Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA kidney renal clear cell carcinoma (KIRC) project

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ricketts, Christopher J ^a   Hill, Victoria K ^b   Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASONUCLIN 1; BIOLOGICAL MARKER; FIBRILLIN 2; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMATID ABERRATION; CHROMOSOME LOSS; COHORT ANALYSIS; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; FBN2 GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE MAPPING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY RENAL CLEAR CELL CARCINOMA; MAJOR CLINICAL STUDY; PREDICTION; PROMOTER REGION; PUBLICATION; SFRP1 GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; VHL GENE;

CARCINOMA, RENAL CELL; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MEMBRANE PROTEINS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898629861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085621     Document Type: Article

References (48)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592 (Pubitemid 46359643)
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, et al. SEER Cancer Statistics Review, 1975-2010, http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013
3. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, et al. (1994) Somatic mutations of the von hippel-lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 3: 2169-2173
4. Latif F, Tory K, Gnarra JR, Yao M, Duh F-M, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320 (Pubitemid 23231974)
5. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91: 9700-9704 (Pubitemid 24311875)
6. The Cancer Genome Altas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49
7. Varela I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542
8. Guo G, Gui Y, Gao S, Tang A, Hu X, et al. (2012) Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44: 17-19
9. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363
10. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, et al. (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45: 860-867
11. Morris MR, Maher ER (2010) Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2: 59
12. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 2000-2011
13. Dulaimi E, Ibanez dC, I, Uzzo RG, Al-Saleem T, Greenberg RE, et al. (2004) Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 10: 3972-3979 (Pubitemid 38812470)
14. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, et al. (2001) Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 61: 7277-7281 (Pubitemid 32946526)
15. Hesson LB, Cooper WN, Latif F (2007) Evaluation of the 3p21.3 tumoursuppressor gene cluster. Oncogene 26: 7283-7301 (Pubitemid 350115980)
16. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, et al. (2010) Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29: 2104-2117
17. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, et al. (2011) Genomewide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30: 1390-1401
18. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, et al. (2009) CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 8: 31
19. Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, et al. (2012) Genomewide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 7: 278-290
20. Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, et al. (2013) Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network. Clin Cancer Res 19: 3259-3267
21. Pawlowski R, Muhl SM, Sulser T, Krek W, Moch H, et al. (2013) Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 132: E11-E17
22. Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, et al. (2009) The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One 4: e6767
23. Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, et al. (2012) GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int 110: E144-E152
24. van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, et al. (2010) Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol 176: 575-584
25. Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, et al. (2005) Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer 50: 43-49 (Pubitemid 41297468)
26. Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, et al. (2009) Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncol Rep 21: 1067-1073
27. Hibi K, Mizukami H, Saito M, Kigawa G, Nemoto H, et al. (2012) FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer Res 32: 4371-4374
28. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, et al. (2007) Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 176: 355-367
29. Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, et al. (2010) Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 116: 1025-1034
30. Yu JS, Koujak S, Nagase S, Li CM, Su T, et al. (2008) PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27: 4657-4665
31. Zhang D, Zhao W, Liao X, Bi T, Li H, et al. (2012) Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer. Oncol Rep 28: 1785-1791
32. Jeanes A, Gottardi CJ, Yap AS (2008) Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27: 6920-6929
33. Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, et al. (2010) Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis 31: 1027-1036
34. Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, et al. (2006) Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66: 4617-4626
35. Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486
36. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, et al. (2009) Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 4: 185-193
37. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, et al. (2010) Genomewide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5: 499-508
38. Boldrup L, Coates PJ, Laurell G, Nylander K (2012) p63 Transcriptionally regulates BNC1, a Pol I and Pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer 48: 1401-1406
39. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, et al. (2007) Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26: 5680-5691 (Pubitemid 47267837)
40. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, et al. (2006) Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 12: 6989-6997 (Pubitemid 44974494)
41. Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O (2008) Methylationassociated silencing of SFRP1 in renal cell carcinoma. Oncol Rep 20: 1257-1263
42. Katoh M, Katoh M (2007) WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042-4045 (Pubitemid 47105963)
43. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, et al. (2009) Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 15: 5678-5687
44. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, et al. (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749 (Pubitemid 47294780)
45. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, et al. (2011) Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 128: 1793- 1803.
46. Kawakami K, Yamamura S, Hirata H, Ueno K, Saini S, et al. (2011) Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer 128: 541-550
47. Kawamoto K, Hirata H, Kikuno N, Tanaka Y, Nakagawa M, et al. (2008) DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 123: 535-542 (Pubitemid 351898410)
48. Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, et al. (2012) Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther 11: 2105-2115